Preventing non-communicable diseases caused by the post-acute phase of cOvid-19 INfecTion

Schrift Standard Fett
Login

Forschungsstelle

SBFI

Projektnummer

23.00493

Projekttitel

Preventing non-communicable diseases caused by the post-acute phase of cOvid-19 INfecTion

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Abstract (Englisch)	The post-acute phase (PAP) of COVID-19, occurring =4 months after the acute phase, is associated with an increased risk for thedevelopment of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acutephase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ functionin the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary,cardiovascular and renal systems due to the PAP. To avoid the significant socioeconomic costs related to this burden, POINT will developknowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, andclinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfilan unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems willhave to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health carevalue chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the developmentof NCDs in general and the risks of PAP from other infectious diseases. POINT will meet the challenges with a holistic approach froma truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists,who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans.Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as adedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.

Kategorie

Text

Abstract
(Englisch)

The post-acute phase (PAP) of COVID-19, occurring =4 months after the acute phase, is associated with an increased risk for thedevelopment of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acutephase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ functionin the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary,cardiovascular and renal systems due to the PAP. To avoid the significant socioeconomic costs related to this burden, POINT will developknowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, andclinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfilan unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems willhave to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health carevalue chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the developmentof NCDs in general and the risks of PAP from other infectious diseases. POINT will meet the challenges with a holistic approach froma truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists,who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans.Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as adedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.